Abstract
Sibutramine is the first of a new generation of weight management drugs, and offers long-term control of weight when used as an adjunct to diet and exercise. This paper considers the criteria set down by the European Union's regulatory agency for its use and how this relates to the information now available on its efficacy, side-effect profile and benefits in different patient groups. The data presented relate to 18–65 y olds; its use in other age groups has not been established. The EU licence permits continuous treatment for periods of up to 1 y; the STORM study has now led the US Food and Drug Administration to extend clearance to 2 y. The addition of sibutramine to a regimen of diet, exercise and lifestyle modification results in 3–5 times more patients responding to a weight-reduction programme, ie achieving more than 5% weight maintenance. Sibutramine is indicated for use in obese patients (BMI >30 kg/m2) and also overweight patients with a BMI >27 kg/m2 who have additional obesity-related risk factors such as type 2 diabetes or dyslipidaemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Astrup, A., Toubro, S. When, for whom and how to use sibutramine. Int J Obes 25 (Suppl 4), S2–S7 (2001). https://doi.org/10.1038/sj.ijo.0801930
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0801930
Keywords
This article is cited by
-
Sibutramine and the sympathetic nervous system in obese humans
Clinical Autonomic Research (2005)
-
Combined Dietary and Pharmacological Weight Management in Obese Hypopituitary Patients
Obesity Research (2004)
-
Sibutramine lost and found
Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity (2002)